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Maternal antibodies provide protection for the developing fetus. Transplacental trans-
port of pathogenic autoantibodies might pose a risk for the developing fetus. The 
transport of antibodies across the placenta to the fetal circulation occurs through the 
neonatal Fc salvage receptor (FcRn). During gestation, maternal autoantibodies are 
able to penetrate the embryonic brain before a functional intact blood–brain barrier 
is established. Brain-reactive antibodies to the water channel protein aquaporin-4 
(AQP4) are a hallmark finding in neuromyelitis optica (NMO), a neurological disease 
that predominantly affects women, many of whom are of childbearing age. AQP4–
IgG mediate astrocytic injury in a complement-dependent fashion. Recent studies 
suggest these antibodies contribute to impaired pregnancy outcome. The aim of the 
study was to investigate the transplacental transport as well as FcRn binding of a 
monoclonal AQP4–IgG cloned from an NMO patient (wild-type antibody) compared to 
five different mutated Fc domain of this antibody containing single amino acid substi-
tutions in the Fc region. All of the Fc-mutated antibodies lack complement-dependent 
cytotoxicity. Four of the five Fc-mutated antibodies showed limited transplacental 
transport in vivo. Three mutated Fc with impaired transplacental transport showed 
persistent binding to rodent FcRn at pH 6 but also at pH 7.2, suggesting that limited 
transplacental transport could be due to diminished release from FcRn. One mutated 
Fc with modestly limited transplacental transport showed diminished binding to FcRn 
at pH 6. This study suggests that mutated Fc with intact transplacental transport 
may be used to study antibody effector functions and Fc with limited transport may 
be used as a carrier to deliver therapies to pregnant woman, while sparing the devel-
oping fetus.
Keywords: maternal antibody, transplacental transport, Fcrn, aquaporin-4 igg, complement-dependent 
cytotoxicity
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inTrODUcTiOn
Antibodies play an essential role in health. During development, 
they have a crucial role in providing the fetus with passive protec-
tion against pathogens. The transfer of immunity from the mother 
to the fetus is dominated by IgG transport across the placenta 
(1). Maternal antibodies cross the placenta beginning around the 
second trimester of the pregnancy (2). Under routine conditions, 
the neonatal Fc salvage receptor (FcRn) regulates antibody half-
life; during pregnancy it also mediates transcytosis of IgG from 
the maternal to the fetal circulation (3). Following internalization 
of IgG by pinocytosis, the binding of IgG antibodies to FcRn 
occurs in acidic early endosomes at pH 6 (4, 5). While unbound 
IgG is degraded, FcRn–IgG complexes are routed away from the 
lysosomal pathway and intact IgG is released at physiological pH 
7.2 when phagolysosome fuses with the plasma membrane (6–9). 
Therefore, both IgG binding to FcRn as well as its release from 
FcRn can influence transplacental transport of antibodies.
Maternal IgG has a protective role during pregnancy, yet 
pathogenic autoantibodies are also transported to the fetus and 
may impair fetal development, resulting in either transient or 
permanent damage to the developing fetus. The severity of the 
insult is determined by several factors, such as the antigenic 
specificity of the autoantibodies, maternal IgG concentration, 
and the gestational stage at which the antigen is expressed.
It is well appreciated that a number of neonatal disorders are 
associated with in utero exposure to pathogenic autoantibodies. 
For example, transport of anti-acetylcholine receptor antibodies 
from mothers with myasthenia gravis can result in either tran-
sient myasthenia gravis or in permanent defects in the neonate 
(10–12) and transplacental transport of anti-Ro antibodies in 
mothers with autoimmune disorders can result in fetal heart 
block or neonatal lupus (13).
Pathogenic autoantibodies are not solely present in individu-
als with autoimmune diseases; they are also present in a subgroup 
of healthy individuals. In fact, mothers of children with autism 
spectrum disorder have an increased frequency of brain-reactive 
antibodies (14), and in utero exposure to brain-reactive antibody 
such as antibody to the neuronal voltage-gated potassium chan-
nel Caspr2, results in neurodevelopmental impairment and 
permanent behavioral alterations in mice (15). Since the fetal 
blood–brain barrier (BBB) is permeable to maternal IgG in mice 
until gestational day E16.5 (16), and in humans most likely until 
the third trimester, the developing brain is a potential target for 
maternal autoantibodies, even when the mother experiences no 
clinical symptoms.
Studies of the pathogenicity of maternal brain-reactive anti-
bodies often employ a model in which the antibodies are injected 
into a pregnant animal at a gestational stage when the antigen of 
interest is expressed and the embryonic BBB allows penetration 
of the antibody to the fetal brain (15, 17–19). Antibodies with 
Fc mutations that alter effector function need to be analyzed for 
transplacental transport in order to determine whether they can 
be used in studies to address the mechanism of action of maternal 
antibodies.
Here, we describe a brain-reactive antibody directed to AQP4 
(AQP4–IgG). Neuromyelitis optica (NMO) is an inflammatory, 
demyelinating neurological disease that predominantly affects 
the optic nerve, spinal cord, and brain. AQP4–IgG testing is 
included as a diagnostic marker of the disease (20) and several 
studies in rodent models have demonstrated its pathogenic-
ity (21, 22). AQP4–IgG is thought to result in tissue damage 
primarily through complement-dependent cytotoxicity (CDC), 
but other effector mechanisms such as antibody dependent 
cell-mediated cytotoxicity may also appear to play a role in the 
disease (23, 24).
Recently, several case reports have suggested that AQP4–IgG 
can have a negative impact on pregnancy outcomes (25); further 
studies are needed to address this question. It is reported that 
women with NMO and AQP4–IgG have a higher rate of miscar-
riages and suffer more often from preeclampsia (25). Whether 
placental or fetal damage results from anti-AQP4 IgG exposure 
and whether the mechanism of injury is complement dependent 
is not known.
In this paper, we compared transplacental transport of a 
human monoclonal AQP4–IgG1 antibody cloned from a patient 
with NMO (22), and five variants containing different point 
mutations in the Fc domain designed to reduce complement 
activation. All the antibodies with mutated Fc were deficient in 
CDC in vitro; however, they differed in their ability to cross the 
placenta. At the time point when less transplacental transport 
was observed, all of the antibodies were present in the blood 
at similar concentrations. Yet, one mutated Fc with impaired 
transplacental transport showed diminished binding to mouse 
FcRn at pH 6, while the other three mutated Fc antibodies with 
severely impaired transplacental transport showed enhanced 
binding to FcRn at pH 7.2, suggesting that the antibodies are not 
as efficiently released from FcRn.
This study emphasizes that single point mutations in the 
Fc region can affect transplacental transport. Our findings are 
important for the study of effector mechanisms by which mater-
nal antibodies mediates fetal pathology. In addition, Fc variants 
with altered transport might also provide clinical application.
MaTerials anD MeThODs
human Monoclonal antibodies
Human monoclonal AQP4–IgG (rAb-53) was cloned from a 
plasmablast recovered from the cerebrospinal fluid of an NMO 
patient, produced, and purified as previously described (22). 
Isotype control (Ctl) was a non-brain binding antibody directed 
against measles virus (2B4-IgG) (22). Recombinant human 
AQP4–IgG (rAb-53) with mutated Fc sequences was generated by 
site directed mutagenesis. Mutation nomenclature is according to 
the EU index as described in Kabat et al. (26) K322A (KA) (27, 28), 
P329A (PA) (28), N297D (ND) (29), D270A (DA) (28), and 
P331G (PG) (28).
cell-Based assay (immunofluorescence)
To confirm binding of wild-type and Fc-mutated antibodies to 
AQP4, we performed a live cell-based assay as previously des-
cribed (30) with some modifications. Briefly, human embryonic 
kidney cells, HEK293T/17 (ATCC), were cultured on poly-d 
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lysine (Sigma) coated glass cover slips (TED PELLA, Inc.) in 
24-well plate. 24  h after seeding the cells, HEK293T/17 cells 
were transiently transfected using FuGene (ProMega) with 
AQP4 (M23 isoform) fused at its C terminus to an emerald 
green fluorescent protein. Two days after transfection the assay 
was performed.
Antibodies (Ctl-IgG, AQP4-IgG, DA-IgG, KA-IgG, ND-IgG, 
PA-IgG, and PG-IgG), 5 µg/ml, were diluted in HBSS/10% FBS 
and incubated with cells for 1  hour at 4°C. Cells were washed 
three times with HBSS/10% FBS and incubated with a second-
ary anti-human antibody Alexa 594 (Invitrogen) for 30 min at 
room temperature. Cells were washed three times, fixed with 4% 
paraformaldehyde (PFA) for 15  min, washed again with HBSS 
and coverslips were mounted on a slide. Pictures were acquired at 
20× magnification using Axio-Imager Z-1 software (Axio-Vision, 
Zeiss, Oberkochen, Germany). Untransfected cells served as 
control. DAPI positive cells, i.e., dead cells, were excluded from 
analysis.
infrared labeling of human Monoclonal 
antibodies
All human monoclonal antibodies were labeled with the IRDye 
800 CW protein labeling kit following the manufacturer’s instruc-
tions (Microscale, Invitrogen). Briefly, the pH level was adjusted 
to 8.5 by adding 1  M potassium phosphate buffer to 200  µl of 
antibody solution (1 mg/ml of IgG in PBS). 1.4 µl of dissolved 
dye was added to the antibody solution and the mixture was 
incubated for 2  h at room temperature. Subsequently, free dye 
was removed using Zeba Spin Desalting columns according to the 
manufacturer’s instructions. Centrifuge columns were washed in 
PBS three times, and excess wash solution was removed by dry 
spin at 1,500 g. The columns were placed in a new collection tube 
and 100 µl of the sample was applied to each column. The tube 
was centrifuged at 1,500 g for 2 min to collect the sample. Integrity 
of labeled antibodies was confirmed using a non-reducing 12% 
Bis-Tris Protein Gel (NuPage, Invitrogen) according to manufac-
turer’s instruction. Gel was stained with Coomassie Brilliant Blue 
Staining (Invitrogen).
To confirm intensity of labeling, dot blots were performed 
with serial dilutions of infrared labeled antibodies, on a nitrocel-
lulose membrane (Biorad, 0.45 µm), drying the membrane and 
scanning for signal intensity. Starting dilution was 20 µg/ml of 
infrared labeled antibody. Membrane analysis was performed 
using the Odysey infrared imaging system (LICOR).
cell-Based assay (for infrared labeled 
antibodies)
Binding to HEK 293 cells expressing AQP4 was confirmed by 
cell-based assay as follows using HEK 293T/17 cells express-
ing AQP4 seeded in a 96-well tissue culture plate as previously 
described (30). In short, cells were incubated with the infrared 
labeled antibodies (1  µg/ml) in triplicates and incubated for 
1 h at 4 C°. Following three washing steps with PBS/10% FBS, 
the liquid was removed and the plate was immediately scanned 
using an infrared imaging system (Odyssey-Licor). The signal 
intensity of transfected and untransfected cells was compared for 
all antibodies. The infrared labeled monoclonal antibody Ctl-IgG 
which does not bind AQP4, was used as control for background 
binding. Untransfected cells were used as controls.
study approval
All animal experiments were performed in accordance with 
the National Institutes of Health Guidelines under protocols 
reviewed and approved by the Institutional Animal Care and 
Use Committee of the Feinstein Institute for Medical Research, 
Northwell Health, Manhasset, NY, USA.
Mice and injection of infrared labeled 
antibody
C57BL/6 mice (6–8 weeks old) were obtained from the Jackson 
Laboratory. For timed pregnancy, 2 female mice and 1 male 
mouse were housed together for 14 h. The time when the male 
mouse was removed from the cage was designated embryonic (E) 
day 0.5. Infrared labeled IgG (60 µg) was administered by retro-
orbital injection in 200 µl volume (300 µg/ml) to time-pregnant 
mice under light anesthesia at E14.5. Embryos were harvested at 
E15.5 as described below. The degree of transplacental transport 
was at least confirmed for 2 litters to each antibody.
infrared scanning of embryos
24 h after injection of the infrared labeled antibodies (Ctl-IgG, 
AQP4-IgG, DA-IgG, KA-IgG, ND-IgG, PA-IgG, and PG-IgG) we 
harvested the embryos with placenta attached and scanned the 
embryo and placenta. An embryo not exposed to an antibody 
was included as an additional control to confirm absence of 
an infrared signal. Scan setting was kept constant for all litters. 
Infrared signal intensity was quantified for each embryo using the 
Odyssey Infrared Imaging System (LI-COR, Linconln, NE, USA) 
and data are presented as ratio of pixel intensity of each embryo 
normalized to the average pixel intensity of an AQP4 litter run 
on the same scan to account for variability within scans. Embryos 
were derived from 2 litters for each antibody.
antibody half-life in serum of Mice
10–20 µg of human IgG (Ctl-IgG, AQP4-IgG, KA-IgG, ND-IgG, 
PA-IgG, and PG-IgG, noninfrared labeled) was injected retrori-
bitally to non-pregnant female C57BL/6 mice (6–8 weeks old). To 
determine levels of human IgG in the serum, mice were eutha-
nized at indicated time points, and blood was collected through 
the orbital sinus. Blood was spun down at 10,000 g for 15 min 
and serum was removed and frozen at −20°C until use. Three 
animals were analyzed for each antibody and blood was drawn 
at different time points (time 0; 3 min after injection, time 0.5, 1, 
2, 4, 6, 24, 48, and 72 h). Serum concentration of human IgG is 
presented (μg/ml). Human IgG levels were measured by ELISA 
as described below and presented as percentage of human IgG at 
24 h relative to time 0.
elisa for Measuring igg concentrations
We used an ELISA to measure human IgG concentrations prior 
to injections and at different time points after injection in the 
serum of mice.
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ELISA plates (Costar) were coated with goat anti-human IgG 
using a concentration of 10 µg/ml and incubated for 1 h at 37°C. 
The plates were washed two times with PBS/Tween and subse-
quently blocked with PBS/3% FBS for an hour at 37°C. Following 
two washing steps with PBS/Tween, samples were diluted in 
PBS/0.3% FBS and incubated at 37°C for 90 min. Human cor-
responding IgG (Ctl-IgG, AQP4-IgG, DA-IgG, KA-IgG, ND-IgG, 
PA-IgG, and PG-IgG) diluted to 200, 100, 50, 25, 12.5, 6.25, 3.125, 
and 1.56 ng/ml was added as a standard. Following four washing 
steps with PBS/Tween AP-conjugated secondary goat anti-human 
IgG antibody (1:1,000 dilution) was added for 1 h at 37°C. Plates 
were washed four times with PBS/Tween. Phosphatase developing 
solution was added and plates were read at 405 nm absorbance 
every 10 min. Concentration of each antibody prior to injection 
was also confirmed using nanodrop.
complement-Dependent cytotoxicity
Complement-dependent cytotoxicity assay was performed as 
previously described (24). CHO cells stably expressing M23–
AQP4 were plated at 37,500 cells/well and cultured overnight 
in CHO cell medium (10% FBS +  1% penicillin/streptomycin/
amphotericin B in F12 media; Gibco). Cells were washed twice 
with pre-warmed F12 medium and incubated at 37°C for 60 min 
with medium alone, 5% pooled human serum (Complement 
Technology, Inc.), or Ab ±  5% pooled human serum. All Ab 
treatments were at 5  µg/ml and were chosen based on a titra-
tion curve previously performed (24). Cells were then washed in 
medium and treated for 15 min with 1 µM Calcein AM (CaAM; 
Invitrogen) to label live cells green and 1 µM propidium iodide 
(PI; Invitrogen) to label dead cells red. Images were taken on a 
Leica inverted fluorescence microscope. Cells were counted using 
ImageJ and the percentage of cell lysis was calculated as [PI posi-
tive cells/(PI positive + CaAM positive cells)] × 100%. Statistical 
analysis was performed using analysis of variance (ANOVA) and 
Dunnett’s test for multiple comparisons in GraphPad Prism 5 
software.
Fcrn Binding Using Octet Fortebio
FcRn binding experiments were performed on an Octet K2 (PALL/
ForteBio) instrument at 30°C, according to ForteBio technical 
note 19 and 34 (https://www.fortebio.com/literature.html). To 
measure FcRn binding, human monoclonal antibodies that were 
not infrared labeled were used and each antibody was analyzed 
using three independent times at two different pH levels, show-
ing comparable results. Anti-human Fab-CH1 biosensors (PALL 
ForteBio) were loaded with monoclonal antibodies (6 µg/ml) in 
kinetic buffer (PALL ForteBio). The concentration of antibody 
was selected by an optimization step as described in technical 
note 19.
For association phase, mouse FcRn-Beta-2 microglobulin 
heterodimer protein (ImmuniTrack) was diluted with assay asso-
ciation and disassociation buffer (100  mM sodium phosphate, 
150 mM Nacl, 0.05% Tween-20, pH 6) to concentrations ranging 
from 2,000 to 0 nM and transferred to solid-black 96-well plate 
(Greiner Bio-One). FcRn was allowed to bind to IgG loaded 
biosensors for 60 s. The dissociation phase was recorded in assay 
buffer pH 6.0 for 60 s.
The experiments at neutral pH were performed as described 
above except that PBS pH 7.2 was used for FcRn dilution, associa-
tion, and dissociation.
All data were referenced with individual AQP4 wild-type 
or mutated Fc antibodies loaded biosensors incubated in assay 
buffer instead of FcRn, and with the biosensor loaded with only 
dilutant and various concentrations of FcRn. The sensorgrams 
were plotted and evaluated using data analysis software version 
9.0 (PALL/ForteBio). Rmax, the maximum response deter-
mined from the fit of the binding data and Req, the calculated 
response at equilibrium that is determined from a fit of the 
binding data are presented. In addition, KD (M) and KD error 
are presented.
statistical analysis
We performed ANOVA followed by Dunnett’s multiple compari-
sons test as well as Student’s t-test for datasets that were normally 
distributed. Otherwise, we performed Mann–Whitney test. All 
tests were performed with the Graph pad prism statistical soft-
ware package. Values were considered significant for p <  0.05. 
Data are presented as mean and error bars represent standard 
error. All tests were two tailed.
resUlTs
Binding to aQP4
Five Fc-mutated antibodies of an IgG1 anti-AQP4 antibody 
were generated, all with an identical light chain and heavy chain 
variable region, but each with a single amino acid substitution in 
the Fc region of the heavy chain. All Fc-mutated antibodies were 
tested for AQP4 binding. As seen in Figure 1, all mutated AQP4 
antibodies bound to AQP4 in a live cell assay.
complement activation
The mutations in the Fc region were designed to decrease 
CDC. We determined that each Fc-mutated antibody dis-
played altered complement activation compared to wild-type 
AQP4–IgG using an in  vitro assay. The wild-type AQP4–IgG 
antibody activated complement as previously described (27). 
Each of the five Fc-mutated antibodies lacked the ability to 
activate the complement cascade, and exhibited diminished 
CDC (Figures 2A,B).
No cell lysis was observed with wild-type AQP4-IgG in the 
absence of human complement, or with isotype-matched  Ctl-IgG 
antibody or medium containing human complement alone 
(Figure 2B; Table 1).
Transplacental Transport of antibodies
In order to investigate transplacental transport of AQP4–IgG 
and the five CDC Fc-mutated antibodies, we injected infrared 
labeled antibody intravenously into pregnant mice. Antibody was 
administrated by retro-orbital injection into pregnant dams on 
embryonic day E14.5 and fetuses were scanned for the presence 
of the infrared labeled antibody 24 h later, a time point when the 
embryonic BBB still allows antibody transport to the brain (16) 
(Figures 3 and 4; Figure S1 in Supplementary Material). Embryos 
FigUre 1 | Cell-based assay demonstrating binding of AQP4–IgG and 
Fc-mutated AQP4–IgG to AQP4 transfected cells. Binding of infrared labeled 
AQP4–IgG and all Fc-mutated antibodies DA-IgG, KA-IgG, PA-IgG, and 
PG-IgG (shown in red) to HEK cells which express AQP4 fused with a green 
fluorescent protein (shown in green). The mutations do not interfere with the 
ability of the antibodies to bind AQP4. The isotype Ctl-IgG, does not bind to 
AQP4 transfected cells. None of the antibodies bind to non transfected cells 
(not shown).
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derived from two litters from each antibody were compared to 
the transport of wild-type AQP4–IgG (Figure  4; Figure S1 in 
Supplementary Material). Whereas Ctl-IgG antibody, wild-type 
AQP4-IgG antibody and the Fc-mutated antibody PA-IgG 
showed equal transport to the fetus, four Fc-mutated antibodies 
exhibited reduced fetal transport; the impact ranged from modest 
(DA-IgG) to severe (KA-IgG, ND-IgG, and PG-IgG) (Figures 3 
and 4; Figure S1 in Supplementary Material). The antibodies that 
entered the fetal circulation could all be observed in the fetal 
brain. Placentas showed similar levels of high infrared signal 
even for mutated antibodies with less transplacental transport, 
as shown for Fc-mutated ND-IgG in Figure S2 in Supplementary 
Material.
Reduced transplacental transport could not be explained 
by a difference in labeling of the antibodies or differences in 
binding to AQP4, since we confirmed that all antibodies had 
the same degree of labeling prior to injection (Figures S3A,B in 
Supplementary Material), and we confirmed that labeling had 
no effect on their ability to bind to AQP4 expressed by trans-
fected HEK293T cells (Figure 1; Figure S4 in Supplementary 
Material). Integrity of the labeled antibodies was confirmed 
with non-reducing SDS Page (Figure S3C in Supplementary 
Material).
The difference in the maternal-fetal transport of infrared 
labeled antibody was not associated with different antibody 
concentrations in the blood at the time point when the transpla-
cental transport was performed (Figure S5A in Supplementary 
Material). Only the DA-IgG antibody showed some trend to 
reduced concentration at 24  h (Figure S5B in Supplementary 
Material).
effect of Mutation on Fcrn Binding
Because the function of FcRn involves IgG binding at pH 6, and 
antibody release at pH 7.2, we assessed all antibodies for pH-
dependent binding to mouse FcRn.
As shown in Table 2 and Figure 5A and Figure S6 in Supple-
mentary Material all antibodies except Fc-mutated DA-IgG 
showed comparable binding to mouse FcRn at pH 6. Rmax and 
Req, but not KD values of DA-IgG indicated reduced binding to 
FcRn at pH 6 compared to the wild-type AQP4 antibody.
As expected, all antibodies bound less well to mouse FcRn 
(2  µM) at pH 7.2 compared to pH 6 (Figure  5B). The three 
Fc-mutated antibodies with the most impaired transplacental 
transport (KA-IgG, ND-IgG, and PG-IgG) demonstrated elevated 
binding to FcRn at pH 7.2, compared to the wild-type AQP4–IgG, 
PA-IgG, and DA-IgG.
DiscUssiOn
Maternal IgG is transferred to the fetus during pregnancy by 
binding to FcRn. In mice, access to the fetal brain is possible until 
around embryonic day E16.5 (16). Studies have indicated the 
possibility that AQP4 antibodies present within the circulation 
of a mother with NMO might also affect the offspring (25, 31), as 
has been shown for some other brain-reactive antibodies (15, 32). 
AQP4 antibodies act primarily through CDC to induce pathology 
in NMOSD patients (23).
In our study, we evaluated the transplacental transport of five 
Fc-mutated AQP4–IgG antibodies which lack complement acti-
vation using a well-established method as previously described 
(16, 17, 32).
Interestingly, we observed that four out of five antibodies 
containing point mutations in the Fc portion that diminish CDC 
effector function had impaired penetration to the fetus when 
injected into a pregnant dam at embryonic day E14.5.
It is known that FcRn binding is required for transport of IgG 
across the placenta in mouse and human. Altering a single amino 
acid in the Fc region of IgG can affect placental transport of IgG, 
through affecting the binding to FcRn (33). Crystal structure 
analysis as well as site-directed mutagenesis have provided some 
TaBle 1 | AQP4–IgG-mutated antibodies with limited complement-mediated 
cytotoxicity.
Treatment % lysis (mean ± sD)
Medium 0.00 ± 0.00
5% hC 0.00 ± 0.00
Ctl-IgG 0.24 ± 0.14
Ctl-IgG + 5% hC 0.36 ± 0.36
AQP4-IgG 0.31 ± 0.31
AQP4-IgG + 5% hC 48.39 ± 0.97
PA-IgG 0.11 ± 0.11
PA-IgG + 5% hC 0.82 ± 0.34
DA-IgG 0.11 ± 0.11
DA-IgG + 5% hC 3.89 ± 1.87
PG-IgG 0.00 ± 0.00
PG-IgG + 5% hC 2.23 ± 0.87
KA-IgG 1.38 ± 0.86
KA-IgG + 5% hC 1.07 ± 0.28
ND-IgG 0.00 ± 0.00
ND-IgG + 5% hC 2.05 ± 1.62
Cell lysis of CHO cells expressing AQP4 (mean percentage ± SD) is presented for 
medium alone, human complement (hC) alone, and Ab without (top) or with (bottom) 
hC. Ctl-IgG antibody is specific for measles virus nucleocapsid protein and serves as a 
negative control. *p < 0.001, analysis of variance with Dunnett’s multiple comparison test.
FigUre 2 | Antibody Fc domain mutations limit complement-dependent cytotoxicity activation by AQP4–IgG. (a) CHO cells expressing M23–AQP4 were incubated 
with 5 µg/ml monoclonal antibody in the absence (left row) or presence (right row) of 5% pooled human serum (hC) for 60 min at 37°C. Live cells are labeled with 
calcein AM, which is a cell viability dye (green); dead cells are labeled with propidium iodide (red). (B) Cell lysis (mean percentage ± SD) is plotted for medium alone, 
hC alone, and each monoclonal antibody without (top) or with (bottom) hC. Ctl-IgG is specific for measles virus nucleocapsid protein and serves as a negative 
control. *p < 0.0001; analysis of variance with Dunnett’s multiple comparisons test.
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close proximity to the FcRn binding site (34–36), therefore, 
altering those amino acids might result in altered FcRn binding. 
Indeed, it has been shown that the histidine residues H310 and 
H435 are critical for the pH-dependent binding of IgG to FcRn 
(34–36). Mutations at these residues lead to decreased binding at 
pH 6.
In our study the substitution DA led to, although significant, 
only a modest reduction of transplacental transport, which could 
be attributed to its reduced ability to bind FcRn at pH 6, as indi-
cated by reduced Rmax and Req values, and a trend to reduced 
concentration in the blood 24 h after injection.
The Fc-mutated ND-IgG, KA-IgG, and PG-IgG had substantially 
diminished transplacental transport compared to AQP4–IgG1. In 
contrast to DA-IgG, these antibodies showed intact FcRn binding 
at pH 6; however, all exhibited slightly enhanced FcRn binding at 
pH 7.2, likely resulting in a failure to be as efficiently released as 
wild-type AQP4-IgG from FcRn engagement at the fetal site of 
the placenta, which could provide one possible explanation for 
limited transport.
While previous studies have shown that the mutations KA 
and DA and P331A (but not P331G) do not affect human 
FcRn binding at pH 6, and PA and N297A (but not N297D) 
have slightly reduced affinity at pH 6 (37), we are not aware of 
literature testing human IgG1 at pH 6 and pH 7.2 with those 
mutations for binding to mouse FcRn. Asparagine 297 is a 
information regarding the FcRn/IgG interaction sites. Particularly, 
amino acid residues at position 252–256 in the CH2 domain and 
positions 310, 433, 434, and 435 in the CH3 domain are at or in 
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FigUre 4 | Quantification of transplacental transport of antibodies. 
Quanitification of optical intensity of the infrared signal (pixel intensity) from 
embryos exposed to maternal infrared labeled antibodies in utero. The values of 
each embryo is averaged and shown normalized to the average pixel intensity of 
an AQP4–IgG exposed litter present on the same scan to account for variability 
within scans (normalized pixel intensity). Transplacental transport of each 
antibody is shown for both litters. One-Way analysis of variance followed by 
Dunnett’s multiple comparisons test revealed that mice injected with PG-IgG, 
KA-IgG, and ND-IgG showed markedly reduced normalized infrared pixel 
intensity compared to AQP4–IgG (**p < 0.0001). DA-IgG showed a modest, but 
significant reduction, infrared pixel intensity compared to AQP4–IgG (*p < 0.005). 
Ctl-IgG, AQP4-IgG, and PA-IgG  are not different (p > 0.8).
TaBle 2 | Binding of antibodies to mouse FcRn.
ph 6 ph 7.2 ph 6 ph 7.2
Req Req Rmax Rmax
Ctl-IgG 0.76 0.03 0.82 0.128
AQP4-IgG 0.8505 0.0948 0.9599 0.1043
PA-IgG 1.1556 0.0365 1.2766 0.0365
DA-IgG 0.43 0.0482 0.45 0.042
Pg-igg 0.915 0.1512 0.9796 0.2728
Ka-igg 0.9868 0.198 1.119 0.4056
nD-igg 1.0028 0.1355 1.1174 0.2152
Binding of antibodies to mouse FcRn at an IgG concentration of 6 µg/ml. Binding is 
shown at equilibrium response Req or as the maximum binding signal Rmax. Binding was 
tested at pH 6 and pH 7.2. All antibodies show equal binding at pH 6, except antibody 
DA-IgG, which has lower binding. Antibodies with enhanced binding at pH 7.2 (ND-
IgG, PG-IgG, and KA-IgG) are shown in bold. Experiments were performed three times 
for each antibody at pH 6 and pH 7.2 and representatives are shown for each antibody.
FigUre 3 | Effect of mutations of AQP4–IgG on transport across the placenta. Infrared labeled AQP4–IgG and its isotype control antibody (Ctl-IgG) as well as the 
Fc-mutated PA-IgG show an equal degree of transplacental transport in the embryo (a). DA-IgG shows modestly diminished transport (B). KA-IgG, ND-IgG, and 
PG-IgG have severely impaired transplacental transport (c). Each antibody was tested in 2 litters at a concentration of 60 µg.
glycosylation site (38), however, there are controversial data 
regarding the effect of altered glycosylation on the transpla-
cental transport (39, 40). Moreover, a previous study has shown 
that human IgG1 has a different affinity for mouse compared to 
human FcRn (41).
Little information is available to explain the lack of transplacen-
tal transport of antibodies with intact binding to FcRn. A mutated 
antibody with a IgG3ΔHinge mutation failed to cross the placenta 
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in a placenta perfusion model but this was not related to a lack of 
human FcRn binding (33).
It also appears that other Fc receptors might be involved in 
transplacental transport of IgG. Evidence for a contribution of 
additional receptors comes from human studies. In humans, 
FcγRIIb is expressed by placental villous endothelial cells, and 
is believed to play a role in transporting IgG across the villous 
endothelium. In mice, FcγRIIb has been shown to mediate IgG 
endocytosis and transcytosis in  vitro, and is expressed in the 
placenta yolk sac vasculature, and thus could function as an 
additional IgG transporter (42). However, it is not clear whether 
this receptor is critical to transport IgG across the placenta, since 
fetuses of mice lacking FcγRIIb show comparable levels of IgG as 
wild-type mice (43).
Transport of IgG from mother to fetus can also be used for 
therapeutic ends by fusing the therapeutic protein to an Fc 
fragment. Grubb and colleagues administered β-glucuronidase 
(GUS) fused to an Fc region to pregnant mice in order to reverse 
GUS deficiency in a mouse model of mucopolysaccharido-
sis (44). It is also possible to envision the use of IgG with an 
altered Fc region to generate a therapeutic agent that will not 
be transported to the fetus and, therefore, will not endanger the 
developing fetus.
We would like to hypothesize that fusing antigen to a mutated 
Fc region that does not cross the placenta but has a reasonable 
half-life might serve as a novel therapeutic strategy in pregnant 
mothers, to prevent the transport of pathogenic IgG to the fetus. 
Fc can improve solubility, stability, and half-life of the fused mol-
ecule, and as in this study, can be manipulated to have reduced 
CDC or other effector mechanisms. Therefore, administrating a 
fusion protein consisting of antigen and mutated Fc during preg-
nancy to absorb pathogenic antibody could theoretically remove 
pathogenic antibody within the mother without affecting the 
developing fetus. Since immune complexes are not transported to 
the fetus, we speculate that the Fc fusion protein will be removed 
by the reticuloendothelial system in the mother or the placenta. 
This strategy is currently being studied. This therapeutic strategy 
could be used to supply decoy antigen not only for AQP4–IgG but 
also for other antibody mediated diseases, where the presence of 
antigen-specific antibodies during pregnancy can adversely affect 
the developing fetus.
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